Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 8,000,000 shares, a growth of 17.5% from the December 15th total of 6,810,000 shares. Currently, 21.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is presently 5.7 days.

Checkpoint Therapeutics Stock Down 4.5 %

NASDAQ CKPT traded down $0.15 on Friday, reaching $3.18. The company had a trading volume of 592,705 shares, compared to its average volume of 2,262,361. The stock has a market capitalization of $155.28 million, a PE ratio of -1.73 and a beta of 1.36. Checkpoint Therapeutics has a 12 month low of $1.38 and a 12 month high of $4.50. The firm’s 50 day moving average price is $3.62 and its 200 day moving average price is $2.91.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, research analysts expect that Checkpoint Therapeutics will post -0.91 EPS for the current year.

Insider Activity at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 268,432 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the sale, the chief financial officer now directly owns 1,032,754 shares of the company’s stock, valued at approximately $4,141,343.54. This represents a 20.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO James F. Oliviero III sold 220,230 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the sale, the chief executive officer now owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. The trade was a 6.45 % decrease in their position. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several institutional investors have recently added to or reduced their stakes in CKPT. Virtu Financial LLC bought a new position in shares of Checkpoint Therapeutics during the 3rd quarter valued at approximately $30,000. XTX Topco Ltd bought a new position in Checkpoint Therapeutics during the second quarter valued at $34,000. Bartlett & CO. Wealth Management LLC lifted its position in Checkpoint Therapeutics by 375.0% during the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $61,000 after purchasing an additional 15,000 shares during the last quarter. Gladstone Institutional Advisory LLC grew its stake in shares of Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after buying an additional 20,500 shares in the last quarter. Finally, Magnus Financial Group LLC increased its holdings in shares of Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after buying an additional 4,000 shares during the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on CKPT shares. D. Boral Capital started coverage on shares of Checkpoint Therapeutics in a report on Monday, January 13th. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Finally, Lake Street Capital lifted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.